Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J MacFarlane

Showing results (781-790 of 806) with videos related to

Pageof 81
Sort By:
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1982
Antihypertensive therapy in patients above age 60 with systolic hypertension. A progress report of the European Working Party on High Blood Pressure in the Elderly (EWPHE)A Amery, W Birkenhäger, M Bogaert, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Arthritis Research & Therapy|January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registriesAdrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Rheumatology (Oxford, England)|December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and responseSara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Annals of the Rheumatic Diseases|July 13, 2026
Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countriesBrigitte Michelsen, Christos Polysopoulos, Michael J Nissen, et al.
Joint Bone Spine|April 6, 2024
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatmentLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, et al.
RMD Open|May 7, 2026
Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritisZohra Faizy Ahmadzay, Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, et al.
Nature Communications|September 7, 2024
Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization studyAbhinav Thakral, John Jw Lee, Tianzhichao Hou, et al.
RMD Open|July 25, 2024
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational studySara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, et al.
Pageof 81

Showing results (781-790 of 806) with videos related to

Sort By:
Pageof 81
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1982
Antihypertensive therapy in patients above age 60 with systolic hypertension. A progress report of the European Working Party on High Blood Pressure in the Elderly (EWPHE)A Amery, W Birkenhäger, M Bogaert, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Arthritis Research & Therapy|January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registriesAdrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Rheumatology (Oxford, England)|December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and responseSara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Annals of the Rheumatic Diseases|July 13, 2026
Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countriesBrigitte Michelsen, Christos Polysopoulos, Michael J Nissen, et al.
Joint Bone Spine|April 6, 2024
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatmentLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, et al.
RMD Open|May 7, 2026
Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritisZohra Faizy Ahmadzay, Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, et al.
Nature Communications|September 7, 2024
Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization studyAbhinav Thakral, John Jw Lee, Tianzhichao Hou, et al.
RMD Open|July 25, 2024
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational studySara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, et al.
Pageof 81